Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 10;3(8):1503–1517. doi: 10.1210/js.2019-00103

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Endocrine Society 2019

This article is a U.S. Government work-for-hire and is therefore in the public domain in the U.S.

PMC Copyright notice

Figure 2. — LDLP parameters in patients with lipodystrophy before metreleptin treatment (black circles) vs healthy controls (open circles). Bars indicate the mean and SEM. (A) Total LDLPs, (B) large LDLPs, (C) medium LDLPs, (D) small LDLPs, (E) LDLP size, and (F) apoB. *P < 0.05 for comparison of controls vs patients with lipodystrophy. Gray shading indicates manufacturer-provided normal range [5th to 95th percentile of a sample of the population (n = 698) of healthy men (n = 284) and women (n = 414) aged 18 to 94 (mean 39 y)].